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Background: Molecular characterisation of single circulating tumour cells (CTCs) holds considerable promise for predictive
biomarker assessment and to explore CTC heterogeneity. We evaluate a new method, the DEPArray system, that allows the
dielectrophoretic manipulation and isolation of single and 100% purified groups of CTCs from pre-enriched blood samples and
explore the feasibility of their molecular characterisation.
Methods: Samples containing known numbers of two cell populations were used to assess cell loss during sample loading.
Cultured breast cancer cells were isolated from spiked blood samples using CellSearch CTC and Profile kits. Single tumour cells and
groups of up to 10 tumour cells were recovered with the DEPArray system and subjected to transcriptional and mutation analysis.
Results: On average, 40% cell loss was observed when loading samples to the DEPArray system. Expected mutations in clinically
relevant markers could be obtained for 60% of single recovered tumour cells and all groups of tumour cells. Reliable gene
expression profiles were obtained from single cells and groups of up to 10 cells for 2 out of 3 spiked breast cancer cell lines.
Conclusion: We describe a semiautomated workflow for the isolation of small groups of 1 to 10 tumour cells from whole blood
samples and provide proof of principle for the feasibility of their comprehensive molecular characterisation.
Advances in molecular biology have revolutionised medical
oncology. Genome-wide expression profiling and next-generation
sequencing studies have revealed considerable, often reproducible,
heterogeneity in the molecular constitution of many tumour types
(Reis-Filho and Pusztai, 2011; Collisson et al, 2012). In addition,
the presence or absence of several specific molecular alterations
*Correspondence: Dr DJE Peeters; E-mail: dieter.peeters@gza.be
Received 21 November 2012; revised 6 February 2013; accepted 8 February 2013; published online 7 March 2013
& 2013 Cancer Research UK. All rights reserved 0007 – 0920/13
FULL PAPER
Keywords: circulating tumour cells; DEPArray; single-cell analysis; personalised cancer treatment; dielectrophoretic cell sorting
British Journal of Cancer (2013) 108, 1358–1367 | doi: 10.1038/bjc.2013.92
1358 www.bjcancer.com |DOI:10.1038/bjc.2013.92
have been shown to predict response to molecularly targeted
treatments (La Thangue and Kerr, 2011). As a consequence,
documentation of several of these markers, such as HER2
amplification in patients with breast cancer or the absence of
activating KRAS mutations in patients with metastatic colorectal
cancer, are now prerequisites before starting treatments targeting
the HER2 and EGFR pathway.
Most of our current knowledge on tumour biology originates
from the interrogation of the primary tumour, although in general
cancer mortality occurs because of the development of metastatic
disease (Mehlen and Puisieux, 2006). In clinical practice, the
analysis of predictive biomarkers is performed on archival tissue
samples from the primary tumour rather than biopsies taken at the
time of metastatic progression. Sampling metastatic lesions is often
technically difficult or not without risk because of anatomical
constraints. Several studies comparing predictive biomarkers on
archival primary tumour tissue and metastatic lesions in patients
with metastatic breast cancer have documented discordances in up
to 25% of cases (Amir et al, 2012; Higgins et al, 2012; Niikura et al,
2012). Even if a biopsy for biomarker assessment is obtained at the
time of metastatic disease, patients often exhibit multiple lesions
that might be composed of different subclones of tumour cells
harbouring different molecular characteristics (Marusyk et al,
2012). In addition, resistance to the selected treatment will
eventually occur in virtually all patients. The occurrence of re-
responses to EGFR tyrosine kinase inhibitors following previous
discontinuation of treatment because of disease progression in
patients with non-small-cell lung cancer (Kurata et al, 2004; Riely
et al, 2007) further illustrates the dynamics of this process over
time. Hence, repetitive probing of drug targets and potential
biomarkers for monitoring drug sensitivity and emerging resis-
tance on contemporary tumour samples is essential to allow for
more dynamic, individualised treatment planning and monitoring
(Diaz et al, 2012; Misale et al, 2012; Shah et al, 2012).
Circulating tumour cells (CTCs) isolated from the blood of
patients with metastatic carcinomas provide an attractive source of
tumour cells available for such contemporary and repeatable
tumour biopsies. The enumeration of CTCs, as performed by the
CellSearch System (Veridex LLC, Raritan, NJ, USA), has FDA-
approved clinical utility as a prognostic marker in patients with
metastatic breast cancer (Cristofanilli et al, 2004), colorectal cancer
(Cohen et al, 2008) and prostate cancer (de Bono et al, 2008). In
addition, genotypic and phenotypic characterisation of therapeu-
tically or biologically relevant biomarkers expressed by CTCs has
been shown to be feasible (Maheswaran et al, 2008; Attard et al,
2009; Ignatiadis et al, 2011; Sieuwerts et al, 2011). Preclinical data
furthermore suggest that CTCs seem a more relevant reflection of
the dominant subclone of tumour cells in the metastatic
compartment (Yu et al, 2012).
The major challenge for the accurate molecular profiling of
CTCs is CTC purification. CTCs are outnumbered by white blood
cells (WBCs) by a factor of at least 106. Current protocols and
technologies enrich rather than purify CTCs, imposing limitations
on the feasibility and reliability of measuring CTC-specific markers
within the overwhelming WBC background. Potentially even more
important, most of the currently available assays do not allow for
the evaluation of clonal and molecular heterogeneity within the
CTC population.
Recently, the DEPArray system (Di-Electro-Phoretic Array
system; Silicon Biosystems (SB, Bologna, Italy)), a semiautomated
system that allows the isolation of rare cells, such as CTCs, from
mixed-cell populations at the single-cell level was developed (Fuchs
et al, 2006). With this technique, fluorescently labelled cells can be
visualised and isolated by means of a chip consisting of various
microelectrodes creating electric cages in which individual CTCs
are trapped. Alternatively activating and deactivating the micro-
electrodes on the chip results in moving the caged cells to a
position in the chip that allows the recovery of these cells in a
medium suitable for downstream analysis.
The aim of this study was to explore the feasibility to isolate and
to molecularly characterise single tumour cells from human blood
samples using this technique in a continuous workflow down-
stream of the CellSearch system, the currently most widely used
CTC isolation and enumeration method. We report on the basic
analytical aspects of the system and provide proof-of-principle data
showing the feasibility to perform both mutation and transcrip-
tional analysis of single tumour cells or small groups of up to 10
tumour cells isolated with the DEPArray from immunomagneti-
cally pre-enriched blood samples.
MATERIALS AND METHODS
Cell lines and culture conditions. The ERþ /PR-/HER2þ
MDA-MB-361, the ERþ /PRþ /HER2 MCF7 and the triple-
negative MDA-MB-231 human breast cancer cell lines were used
for blood spiking experiments. Cell lines were chosen based on the
presence of known mutations in the MDA-MB-231 cell line
(COSMIC Database: http://www.sanger.ac.uk/perl/genetics/CGP/
cosmic?action=sample&id=905960&display=mutation) and their
distinct transcriptional profiles (Neve et al, 2006). Cell lines were
cultured in RPMI-1640 medium containing 10% FBS, 1%
glutamine and 1% antibiotics and antimycotics (all from
Invitrogen, Gent, Belgium) at 37 1C in a 5% CO2 atmosphere.
Blood spiking experiments. A total of 7.5ml blood samples
spiked with 103 cells of the above-mentioned cell lines were used
for the isolation of tumour cells for mutation and transcriptional
analysis. Blood samples were collected from two healthy volun-
teers. Tumour cells were harvested from near-confluent culture
flasks according to the ATCC guidelines (ATCC, Manassas, VA,
USA). The number of harvested cells was determined using
a Fuchs-Rosenthal counting chamber (Marienfeld-Superior, Lauda-
Ko¨nigshofen, Germany). Cells were washed once, resuspended
and serially diluted in RPMI-1640 to a final concentration
of 103 cells per 100 ml culture medium. From this final cell
suspension, 100 ml was subsequently added to a 7.5-ml normal
blood sample and processed immediately on the CellSearch system
as described below. From each culture flask used for harvesting
tumour cells for spiking experiments, an additional 3–5 million cells
were harvested for the isolation of DNA and RNA – performed
with the AllPrep DNA/RNA Micro Kit (Qiagen, Valencia,
CA, USA) – that served as a positive internal control in the
downstream analyses.
Immunomagnetic enrichment and sample staining procedures.
The overall experimental workflow is illustrated in Figure 1. To
allow both mutation and transcriptional analysis of isolated tumour
cells, two different sample preparation procedures were used.
In the first procedure, standard protocols and reagents for CTC
isolation and enumeration with the FDA-approved CellSearch
CTC kit (Veridex LLC) were used. Briefly, tumour cells were
spiked in 7.5ml healthy donor blood collected in a CellSave
Preservative Tube (Veridex LLC). Tumour cell isolation and
enumeration were performed using the CellSearch CTC Kit. With
this assay, EpCAM-based immunomagnetically enriched cells are
fluorescently counter labelled with DAPI, which stains the cell
nucleus, PE-conjugated antibodies directed against cytokeratins
(CKs) 8/18/19 and APC-conjugated antibodies directed against
CD45, which stains remaining WBCs. After processing the samples
on the CellSearch system, Veridex cartridges were stored protected
from light at 4 1C until further use. Sample aspiration from the
CellSearch cartridge and volume adjustment for transfer into the
DEPArray cartridge were performed as described below under the
section ‘Sample transfer from CellSearch to DEPArray cartridges’.
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As CellSave Preservative tubes and the CellSearch CTC kit
contain preservative and fixation reagents that might inversely
affect RNA quality, a separate procedure was developed to enable
the isolation of tumour cells that could be used for both mutation
and transcriptional analysis. For this procedure, tumour cells were
spiked in 7.5ml EDTA anti-coagulated healthy donor blood and
isolated using the CellSearch Profile Kit (Veridex LLC). Samples
were subsequently stained using a manual staining protocol.
Briefly, samples were centrifuged for 15min at 300 g and the pellet
was resuspended in 80 ml autoMACS Running Buffer (Miltenyi
Biotec, GmbH, Bergisch Gladbach, Germany). Samples were
incubated with 20 ml PE-conjugated anti-EpCAM antibody (clone
0.N.276, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
10min at 4 1C and 10ml APC-conjugated anti-CD45 antibody
(clone 5B1, Miltenyi Biotec) for another 10min at 4 1C. After
blocking the reaction by adding 1ml of autoMACS Running
Buffer, 1 ml Hoechst 33342 (Sigma, St Louis, MO, USA)
(10mgml 1 concentration) was added and samples were
incubated for 5min at room temperature. After 10min of
centrifugation at 300 g, cells were washed in RPMI-1640 culture
medium and finally resuspended in 14 ml of RPMI-1640.
Sample transfer from CellSearch to DEPArray cartridges. To
allow loading of samples from CellSearch cartridges – containing
325–350ml of sample – in a DEPArray cartridge – typically loaded
with 14 ml of sample – CellSearch CTC samples were aspirated
from their CellSearch cartridge using a 200 ml gel loading tip pre-
rinsed in a 2% BSA in PBS solution. To ensure maximal cell
transfer, CellSearch cartridges were rinsed twice with a 325 ml
aliquot of SB115 buffer (SB), a proprietary low-conductivity buffer
for sorting fixed cells in the DEPArray cartridge. The whole
suspension was centrifuged for 10min at 300 g, cells were washed
once in 1ml of SB115 buffer and finally resuspended in 14 ml of
SB115 buffer.
DEPArray procedure. Cell sorting experiments were performed
as described in the manufacturer’s instructions. Briefly, DEPArray
cartridges were manually loaded with 14 ml of sample and 800 ml of
the buffer solution in which purified or single tumour cells had to
be recovered. After loading the cartridge into the DEPArray
system, B9.26 ml of sample was automatically injected by the
system into a microchamber of the cartridge where the cells were
spontaneously organised into a preprogrammed electric field
consisting of 16 000 electrical cages in which individual cells are
trapped. Image frames covering the entire surface area of the
microchamber for each of three fluorescent filter cubes (PE, APC
and DAPI/Hoechst) and bright field images were captured. Cells
were automatically detected by the system based on a DAPI/
Hoechst fluorescence threshold and were assigned a unique cell ID.
Captured images were digitally processed and presented in a
software module that enables selection of cells of interest by the
operator. Next, for recovery selected cells were moved simulta-
neously to a parking area adjacent to the main microchamber in
the cartridge. Individual cells or groups of cells were subsequently
moved to a recovery area where a last visual confirmation of cell
presence can be performed. To recover a cell or group of cells, the
content of the recovery area was flushed with two drops of buffer
(ca. 30–40 ml) into a 200 ml PCR tube. The entire cell routing
process was monitored under bright field imaging. Routing paths
were automatically calculated by the software. Routing parameters
such as speed can be manually adjusted according to the observed
cellular moving properties.
103  MDA-MB-231,
MDA-MB-361 or MCF7 CellSearch CTC Kit
CK-PE (TC)
CD45-APC (WBC)
DAPI (nucleus)
1
2
7.5 ml whole blood
healthy volunteer
CellSearch profile kit Manual staining
procedure
EpCAM-PE (TC)
CD45-APC (WBC)
Hoechst (nucleus)
3
Loading DEPArray
cartridge (14 l )
4
Analysis and sorting with
the DEPArray system
5
6
Isolation of single cells and groups of cells.
Transcriptional analysis
Figure 1. Schematic of overall experimental workflow. Step 1: Tumour cells of three different human cultured breast cancer cell lines were spiked in
healthy donor blood at a concentration of 103 tumour cells per 7.5ml whole blood. Step 2: Tumour cells were immunomagnetically enriched
using either the CellSearch CTC kit or the CellSearch Profile kit followed by a manual staining procedure. Step 3: Cells were reconstituted in a final
volume of 14ml and loaded in a DEPArray cartridge. Step 4: Analysis and sorting procedures were performed on the DEPArray system.
Step 5: Single cells and groups of cells of interest were isolated with the DEPArray system. Step 6: Mutation or transcriptional analysis of isolated
tumour cells.
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Evaluation of cell loss during loading of DEPArray cartridges.
To evaluate the extent of cell loss that occurs during loading of a
DEPArray cartridge and sample injection into the main micro-
chamber, counting experiments were performed using CellSearch
CTC control samples (CellSearch CTC control kit, Veridex LLC),
processed with the CellSearch CTC kit as an internal quality control
for routine CellSearch CTC analysis in our lab. Each of these
samples contain two populations of fixed SK-BR-3 breast cancer
cells at different concentrations that can be distinguished from each
other by use of fluorescent dyes specific for each population (i.e.,
one population of APC-positive cells present at a concentration of
±60 cells per sample and another population of FITC-positive
cells present at a concentration of ±1000 cells per sample). After
enrichment and enumeration of both cell populations on the
CellSearch system, CellSearch cartridges were removed from their
Magnest (Veridex LLC) and stored protected from light at 4 1C until
enumeration of the same sample was performed on
the DEPArray. Sample transfer from the CellSearch cartridge to
the DEPArray cartridge was performed as described above. The
percentage of cells enumerated on the CellSearch system that could
be re-identified on the DEPArray system was used as a measure to
estimate the total extent of cell loss.
Mutation analysis of DEPArray-purified MDA-MB-231 cells
pre-enriched with the CellSearch CTC kit. A total of 1000 MDA-
MB-231 cells harbouring known mutations in the BRAF, KRAS,
TP53 and NF2 genes were spiked in 7.5ml blood. The sample was
processed with the CellSearch CTC kit and the CellSearch cartridge
was stored at 4 1C for 8 days. Tumour cells visualised on the
DEPArray were defined using standard CellSearch CTC criteria as
described elsewhere (Riethdorf et al, 2007). Isolations of 3 single
tumour cells and 1 group of 10 tumour cells were performed with
the DEPArray in SB115 buffer. Recovered samples were 1 : 3
diluted with molecular grade water and centrifuged for 30min at
maximum speed in a microcentrifuge. Subsequently, 100 ml of
supernatant was aspirated, leaving B20ml of diluted buffer, and
samples were stored at  80 1C until further use. To allow
genotyping analysis on the nuclear material of as few as a single
cell, whole genome amplification (WGA) was performed using the
Ampli1 WGA kit (SB). Samples were thawed on ice and vacuum
centrifuged in a SpeedVac concentrator (Thermo Savant, Thermo
Scientific, Waltham, MA, USA) for B20min to concentrate the
sample volume to B1ml, the starting volume of the WGA
procedure. Global amplification consisting of DNA isolation, MseI
restriction digest, adaptor ligation and PCR amplification were
performed as described in the manufacturer’s instructions. Whole
Table 1. Counting experiments of CellSearch CTC control samples on the DEPArray system
FITCþ cells APCþ cells
Experiment
Time between
CS and DA
experiment (days) CS count DA count DA/CS% CS count DA count DA/CS%
1 6 1026 766 75% 59 43 73%
2 1 1120 465 42% 70 26 37%
3 0 1142 567 50% 72 40 56%
4 0 1083 729 67% 81 47 58%
5 1 1032 454 44% 60 35 58%
6 5 1037 652 63% 41 26 63%
7 9 1070 823 77% 62 43 69%
8 15 1083 663 61% 51 33 65%
9 6 1197 898 75% 57 42 74%
10 5 973 656 67% 67 56 84%
Mean±s.d. 5±4 1076±61 667±137 62±12% 62±11 39±9 63±12%
CV 93% 6% 21% 20% 17% 23% 19%
Minimum 0 973 454 42% 41 26 37%
Maximum 15 1197 898 77% 81 56 84%
Abbreviations: APC¼ allophycocyanin; CS¼CellSearch CTC test; CTC¼ circulating tumour cell; CV¼ coefficient of variation; DA¼DEPArray; FITC¼ fluorescein isothiocyanate. Results of 10
different experiments are summarised. The percentage of cells enumerated on the CellSearch system that could be re-identified on the DEPArray system was used as a measure to estimate
overall cell loss during DEPArray cartridge loading.
Table 2.Multigene mutation analysis of single tumour cells and groups of
tumour cells isolated with the DEPArray system from a CellSearch
cartridge
Gene Mutation Control
Single
cell 1
Single
cell 2
Single
cell 3
Pool of
10 cells
ARID1A 2830C4T WT WT NC NC WT
BRAF 1391G4T MUT MUT WT MUT MUT
KRAS 38G4A MUT MUT MUT MUT MUT
NF2 691G4T MUT MUT NC MUT MUT
PIK3CA 3140A4G WT WT WT WT WT
PIK3CA 333G4C WT WT WT NC WT
TP53 853G4A WT WT WT WT WT
TP53 580C4T WT WT NC NC WT
PIK3CA 1633G4A WT WT WT WT WT
TP53 839G4A MUT MUT MUT MUT MUT
Abbreviations: Control¼ unamplified DNA of 3–5 million MDA-MB-231 cells harvested from
the same culture flask as the one used to perform the isolation of single cells and the group
of tumour cells; MUT¼mutant allele detected by the iPlex assay; NC¼ no call; WT¼only
wild-type allele detected by the iPlex assay. The bold entries indicate that no reliable call
could be obtained based on the iPlex analysis.
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genome amplification products were subjected to an end-point
PCR for two control genomic DNA sequences of 373 and 167 bp,
respectively (Ampli1 Quality Control kit; SB) and PCR products
were analysed by gel electrophoresis on an Agilent 2100
Bioanalyzer using the DNA 1000 kit (Agilent Technologies, Santa
Clara, CA, USA). Only samples positive for both PCR products
were considered to contain successfully amplified genomic material
suitable for mutation analysis. DNA concentrations of the final
WGA products were measured using a Nanodrop ND1000
(NanoDrop Technologies, Waltham, MA, USA) and 50 ng of the
amplified DNA product was subjected to mutation analysis for a
panel of 10 mutations (Table 2) using a Sequenom MALDI-TOF
MassARRAY multiplex PCR and genotyping assay (iPlex assay;
Sequenom Inc., San Diego, CA, USA) as described previously
(Reumers et al, 2011).
Mutation analysis of DEPArray-purified MDA-MB-231 cells
pre-enriched with the CellSearch Profile kit. A total of 1000
MDA-MB-231 tumour cells were spiked in 7.5ml EDTA anti-
coagulated blood and processed according to the CellSearch Profile
procedure in two different experiments. Samples were sorted on
the DEPArray in RPMI-1640 medium. In each experiment, 11
recoveries were performed consisting of 1 blank buffer sample
acting as the negative template control (NTC), 5 single tumour
cells, 1 group of 5 tumour cells, 1 group of 10 tumour cells and 2
groups of 20 WBCs. An additional buffer sample was isolated
between the last tumour cell recovery and the first recovery of
WBCs to check for contamination between recoveries. Samples
were briefly spun down in a microcentrifuge, diluted with 100 ml of
PBS and centrifuged at maximum speed for 30min after which
supernatant was carefully aspirated to leave B1ml. Samples were
stored at  80 1C until further use. Quality control and WGA were
performed using the Ampli1 WGA kit as described above. Half of
the amplified DNA was subjected to KRAS mutation analysis using
a TheraScreen KRAS PCR kit (Qiagen).
Transcriptional analysis of DEPArray-purified tumour cells
pre-enriched with the CellSearch Profile kit. A total of 1000
MDA-MB-231 cells, MDA-MB-361 cells and MCF7 cells were
spiked in 7.5ml EDTA anti-coagulated blood and processed
according to the CellSearch Profile procedure in three different
experiments. Samples were sorted on the DEPArray in RPMI-1640
and isolations of 1 or 2 single tumour cells, groups of 3 to 10
tumour cells and a group of 10 WBCs were performed.
Transcriptional analysis was performed as described previously
(Sieuwerts et al, 2009b). Briefly, cells were lysed immediately after
isolation with the DEPArray in 250ml RLT buffer Plus (Qiagen) and
stored at  80 1C. RNA isolation was performed with the RNeasy
Micro Kit (Qiagen). The cDNA synthesis and 15 cycles of pre-
amplification were performed with the RevertAid H Minus First
Strand cDNA Synthesis Kit (Fermentas, Thermo Fisher Scientific,
Waltham, MA, USA) and the TaqMan PreAmp amplification
method (Applied Biosystems (ABI, Foster City, CA, USA)),
respectively. Pre-amplified cDNA products were subjected to real-
time PCR amplification for nine marker genes and five reference
genes (ACTB, TBP, GUSB, HMBS and HPRT1) to control for
sample loading and RNA integrity. Marker genes were chosen based
on their potential to cover clinically relevant heterogeneity in CTC
populations and included the epithelial-specific marker EPCAM;
adhesion and invasion markers CDH1 and CDH2; markers specific
for breast cancer subgroups CAV1, ESR1, GATA3, ERBB2 and
GRB7; and the WBC marker PTPRC, the gene encoding for CD45.
Assay IDs of TaqMan Gene Expression Assays (ABI) can be found
in Supplementary Table 1. Fluorigenic PCR reactions were
performed in 40 cycles in a final volume of 20ml using TaqMan
Gene Expression Assays and Taqman Universal PCR Master Mix
No AmpErase UNG according to the manufacturer’s instructions
on a 7900HT Fast Real-time PCR System (all from ABI). Each
sample was analysed in duplicate and mean Ct values were used for
further analysis. Negative controls included an RPMI-1640 buffer
sample and minus RT samples from pools of RNA of each cell line.
Only samples with a Ct value ofo35 for each of the individual five
reference genes, and a median Ct value for all reference genes of
o30, were considered of sufficient quality and quantity to be
included for further analyses. Gene expression values were
quantified relative to a standard curve constructed for each marker
transcript with a four-fold serial dilution of cDNA reverse
transcribed from QPCR Human Reference Total RNA (Agilent
Technologies) at an input ranging from 20ng RNA to 20 pg total
RNA. Calculated relative gene expression values with a correspond-
ing Ct value of X35 were set to zero and data were autoscaled as
such that, for each marker, the median relative gene expression level
and the s.d. across all samples equalled 0 and 1, respectively.
Normalised gene expression levels were compared across samples
using the Mann–Whitney U-test. Correlations of gene expression
data between samples were calculated using Pearson’s correlation
statistics. Unsupervised hierarchical clustering was performed based
on the Pearson’s correlation distance between samples with
complete linkage as the dendrogram drawing method.
RESULTS
Evaluation of cell loss during loading of DEPArray cartridges.
The DEPArray cartridges are typically loaded with 14ml of a
fluorescently labelled single-cell suspension. To prevent the
injection of air in the main microchamber of the cartridge where
the visualisation and sorting of the cells occur, onlyB9.26ml of the
total 14ml is injected into this microchamber by the system. As this
implies an analytically dead volume of 4.74ml in the microfluidic
channels of the cartridge, a cell loss of B34% is expected.
Additional cell loss might also occur because of manual sample
volume adjustments and pipetting errors. In order to estimate the
realistic extent of cell loss during this entire sample loading step, we
first performed counting experiments using CellSearch CTC control
samples processed with the CellSearch CTC kit. After being
processed on the CellSearch System, CellSearch cartridges were
stored at 4 1C for a mean duration of 5 days (maximum 15 days)
before analysis on the DEPArray system. Results of 10 different
experiments are summarised in Table 1. Representative images of
cells visualised by the DEPArray system are shown in
Supplementary Figure 1. On average, a cell re-identification rate –
defined as the percentage of cells counted on the CellSearch system
that were available for cell sorting after loading into the DEPArray
cartridge – of 62–63% was obtained. An acceptable degree of
variation (CV 19–20%) was observed between samples, with a
minimum recovery of 37% (63% cell loss) in one experiment.
Similar recovery rates were obtained for the sparse APC-positive
cells as well as for the more abundant FITC-positive cell population.
Mutation analysis of DEPArray-purified MDA-MB-231 cells
pre-enriched with the CellSearch CTC kit. To explore the
feasibility to perform mutation analysis on single CTCs isolated
with the DEPArray from CellSearch cartridges processed for
standard CellSearch CTC enumeration, MDA-MB-231 cells were
purified from a spiked blood sample pre-enriched with the
CellSearch CTC kit. Three single tumour cells and one group of
10 tumour cells were isolated with the DEPArray and analysed for
the presence of 10 different mutations in 6 genes with a customised
iPlex assay. Mutation profiles were compared with that of genomic
DNA extracted from 3 to 5 million cells harvested from the same
culture flask. Illustrative cell images are shown in Figure 2. Results
of the mutation analysis are summarised in Table 2. Call rates of
the amplified genomic sequences were 80% for the single-cell
samples and 100% for the 10-cell sample. Of the 10 mutations
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covered by the iPlex assay, 4 (BRAF_G1391T, KRAS_G38A,
TP53_G839A and NF2_G691T) have been documented in the
MDA-MB-231 cell line (COSMIC Database). All expected mutations
were reliably detected in 2 out of 3 single-cell samples and the 10-cell
sample. In one single-cell sample, two mutations remained
undetected. In this sample, for BRAF, only wild-type sequence was
detected, whereas no reliable call could be obtained for NF2.
Mutation analysis of DEPArray-purified MDA-MB-231 cells
pre-enriched with the CellSearch Profile kit. To enable the
transcriptional analysis of tumour cells isolated with the DEPAr-
ray, a separate workflow that allows the isolation of unfixed
tumour cells using the CellSearch Profile kit and a manual staining
procedure was developed. To evaluate the performance of this
protocol, we first subjected MDA-MB-231 tumour cells isolated
with this procedure to a mutation analysis with the TheraScreen
KRAS PCR kit (Qiagen), which allows detection of the G38A KRAS
mutation, heterozygously present in this cell line (COSMIC
Database). Results of two different experiments are summarised
in Table 3. In line with their known low constitutive EPCAM
expression (Sieuwerts et al, 2009a), an extremely poor EpCAM
staining was observed for the MDA-MB-231 cells during
visualisation on the DEPArray. As a consequence, tumour cells
were selected mainly based on morphological criteria such as size
and high nuclear–cytoplasmic rate and the absence of CD45-APC
staining. A total of 5 single tumour cells, 2 groups of 5 to 10
tumour cells and 2 groups of 20 WBCs were isolated and subjected
to WGA in each experiment. In both experiments, genomic DNA
was successfully amplified according to Ampli1 end-point PCR
criteria, in 3 out of 5 (60%) single tumour cells and all groups of
5–10 tumour cells and WBCs (Figure 3). No amplification product
of either of the two control PCR fragments could be detected in
two single-cell samples in each experiment, suggesting cell loss due
to aspiration of the cell during the preparation for the WGA
procedure. No control PCR product was detected in any of the
blank buffer samples that served as NTC and carryover control
between tumour cell and WBC recoveries. The G38A KRAS
mutation was detected in all successfully amplified tumour cell
samples and in none of the four successfully amplified WBC
samples, indicating 100% purity of the sorted samples.
Transcriptional analysis of DEPArray-purified tumour cells pre-
enriched with the CellSearch Profile kit. Finally, we investigated
the feasibility to perform transcriptional analysis of single cells
enriched from spiked blood samples with the CellSearch Profile kit
and further purified with the DEPArray system. For this purpose,
we performed spiking experiments with three human breast cancer
cell lines exhibiting strongly different expression levels for nine
marker transcripts. Single tumour cells, groups of tumour cells and
groups of WBCs were isolated and subjected to quantitative real-
time RT–PCR analysis. For the samples of the MDA-MB-361 cell
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Figure 2. Composite image gallery showing staining characteristics of MDA-MB-231 cells and WBCs from a CellSearch cartridge after
immunomagnetic enrichment with the CellSearch CTC kit visualised on the DEPArray system. (A) Tumour cells were defined using standard
CellSearch CTC criteria being (1) round to oval shape, (2) presence of a clear DAPI-stained nucleus, (3) at least 50% overlap between the
CK-PE-positive cytoplasm and the nucleus and (4) CD45-APC negativity. Separate images for PE, DAPI and APC fluorescence and bright field
channels and merged CK-PE/DAPI and CD45-APC/DAPI images of three single MDA-MB-231 cells (top 3 rows) and two WBC (bottom 2 rows)
are shown. (B) Scatter plot of mean fluorescence intensities for CK-PE (y axis) and CD45-APC (x axis) staining by the DEPArray software.
Rectangular gates can be applied to aid quick identification of cells or populations of cells for cell sorting. Green dots represent CKþ /CD45
MDA-MB-231 cells selected by the user. Red dots represent CK /CD45þ WBCs. Grey dots represent unselected events.
Table 3. KRAS mutation analysis of single MDA-MB-231 tumour cells and
groups of tumour cells isolated with the DEPArray system from two
manually stained CellSearch Profile samples
Experiment 1 Experiment 2
Sample
Ampli1
QC PCR
G13D KRAS
mutation
Ampli1
QC PCR
G13D KRAS
mutation
NTC Failed NC Failed NC
Single TC 1 Failed NC Failed NC
Single TC 2 Failed NC Passed MUT
Single TC 3 Passed MUT Passed MUT
Single TC 4 Passed MUT Failed NC
Single TC 5 Passed MUT Passed MUT
Group of 5
TCs
Passed MUT Passed MUT
Group of 10
TCs
Passed MUT Passed MUT
Buffer Failed NC Failed NC
Group of 20
WBCs
Passed WT Passed WT
Group of 20
WBCs
Passed WT Passed WT
Abbreviations: MUT¼mutant; NC¼no call; NTC¼ negative template control; QC¼quality
control; TC¼ tumour cell; WBC¼white blood cell; WT¼wild type. Results of Ampli1 QC
PCR for two control genomic DNA sequences and TheraScreen analysis are shown.
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line, reliable qPCR amplification could not be obtained for three
out of five reference genes, indicating poor RNA quality. These
samples were excluded from further analysis. Examples of the
staining characteristics of MDA-MB-231, MCF7 cells and WBCs
and results of the gene expression analysis are shown in Figure 4.
Similar to what was observed in the previous experiment, EpCAM-
PE staining intensity was poor to absent in a majority of MCF7
tumour cells and in almost all MDA-MB-231 tumour cells.
Therefore, tumour cells had to be distinguished from WBCs
mainly based on morphological criteria including larger size and
nuclear–cytoplasmic rate and strict CD45-APC negativity. On gene
expression analysis, all tumour cell samples of both cell lines were
negative for PTPRC whereas groups of WBCs were strongly positive
(P¼ 0.012). Significantly higher gene expression values were
observed in luminal MCF7 cells as compared with triple-negative
MDA-MB-231 cells for CDH1 (P¼ 0.019), ESR1 (P¼ 0.018),
GATA3 (P¼ 0.029) and EPCAM (P¼ 0.020). Conversely, CAV1
(P¼ 0.020) was expressed at significantly higher levels in MDA-
MB-231 cells as compared with MCF7 cells. Gene expression
profiles of single cells and groups of cells were highly correlated
with gene expression profiles obtained from positive control
samples (Pearson R2 (mean±s.d.) for MCF7 cells and MDA-MB-
231 cells, respectively: 0.82±0.20 and 0.62±0.11). Hierarchical
clustering of the gene expression profiles of these MDA-MB-231
and MCF7 samples together with a WBC sample from each of both
experiments demonstrated a clear separation between the three
different cell types, driven by the differential gene expression of
ESR1, GATA3, CDH1, EPCAM, CAV1 and PTPRC.
DISCUSSION
We describe a new method for the isolation of single tumour cells
and completely purified groups of multiple tumour cells from
immunomagnetically pre-enriched blood samples using two
different sample preparation workflows. With this approach, we
provide proof of principle demonstrating the feasibility to
molecularly characterise 1 to 10 tumour cells on both genomic
and transcriptional levels. Taken together, expected mutations
could be detected in 60% of the recovered (n¼ 13) and all
successfully whole genome amplified (n¼ 9) single tumour cells
and groups of tumour cells (n¼ 5) isolated from both fixed and
unfixed cell samples. Importantly, all carryover control samples
and WBC samples were negative for epithelial markers, indicating
high purity of the samples and specificity of the applied
procedures. Additionally, reliable gene expression profiles for a
limited set of 9 markers could be obtained for single tumour cells
and groups of tumour cells from two out of three blood spiked
breast cancer cell lines.
Standardised and reliable methods for the isolation and
molecular characterisation of CTCs at the single-cell level are of
considerable interest to CTC research for several reasons. First,
CTCs encompass an extremely rare cell population. Therefore,
technologies capable of handling small numbers of cells are needed
in order to be able to maximise the amount of information that can
be derived from them. Second, single-cell isolation allows the
complete elimination of the WBC background resulting in pure
CTC samples, a considerable advantage for molecular analysis.
Third, single-cell resolution provides clinicians and researchers
with the unique opportunity to directly investigate the molecular
heterogeneity of CTCs on a cell per cell basis, the smallest
functional unit of cancer.
Several techniques for the manipulation and isolation of single
micrometastatic tumour cells such as CTCs and their disseminated
counterparts in the bone marrow of patients with cancer have been
described. The frequently used strategies include micromanipula-
tion (Klein et al, 2002; Pierga et al, 2005; Hannemann et al, 2011;
Powell et al, 2012) and laser capture microdissection (Kroneis et al,
2011; Sakaizawa et al, 2012) in combination with some antibody-
based or physical pre-enrichment procedure. Many of these
techniques have shown promising results with respect to the
information that can be derived from single cells from both a
biological and a clinical perspective. In addition, several micro-
fluidic devices enabling single tumour cell manipulation, sorting
and analysis have been described (Wlodkowic and Cooper, 2010).
Direct comparisons between different single-cell isolation techni-
ques are currently lacking. The choice of which technique is best to
be used in a specific setting will depend to a large extent on the
purpose of the analysis (research or clinical use), the throughput
needed, compatibility with downstream applications and available
upstream sample preparation procedures as well as personal
experience. From our point of view, the most important advantages
of the DEPArray system are the ability to obtain multiparametric
immunofluorescent staining characteristics of individual cells
before isolation, the ease of operating the system and the possibility
to implement the system in a continuous semiautomated workflow
with, for example, the CellSearch system. Interestingly, in this
study CellSearch cartridges were stored for up to 15 days without
inversely affecting processing on the DEPArray system, providing
valuable flexibility in the planning of isolation experiments if such
techniques are to be applied in a multicentre or clinical setting.
Furthermore, all imaging data obtained before recovering the cells
are digitally stored, allowing integration of staining characteristics
of therapeutically relevant targets such as the level of HER2 protein
expression with molecular information of the same cells.
However, the multiparametric imaging and isolation capabilities
of single CTCs that can be achieved with the DEPArray system
come at a cost. An important issue when studying rare cell
populations such as CTCs is the degree of cell loss that occurs
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Figure 3. Composite gel images of Ampli1 QC end-point PCR products of Ampli1 whole-genome amplified DNA of five single MDA-MB-231
tumour cells and two groups of tumour cells and WBCs used for KRASmutation analysis, analysed on the Agilent 2100 Bioanalyzer. Genomic DNA
of samples was considered to be successfully amplified if both of two control genomic DNA sequences were visualised. In this example, no
amplification product was obtained in two single-cell samples and both negative control samples. No mutated or wild-type allele sequences
were detected with the Therascreen KRAS mutation test in both single-cell samples that failed to pass Ampli1 amplification check (Table 3,
experiment 1). NTC¼ negative template control; TC¼ tumour cell; WBC¼white blood cell.
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during the preparation and isolation of samples. Therefore, we
have tried to estimate the extent of cell loss that has to be taken
into account when processing CellSearch samples on the
DEPArray. CellSearch CTC Control samples that had been
enumerated on the CellSearch system were chosen as a model for
this because they contain known numbers of two distinct cell
populations in different concentrations. Our results indicate that on
average 40% cell loss has to be taken into account in this setting. An
acceptable degree of variability was observed between different
samples with a minimum cell loss of B20% and a maximum cell
loss ofB60% observed across 10 experiments. As this is an artificial
model, it is unclear how this reflects the true extent of cell loss that
can be expected when analysing CellSearch CTC samples from
patients on the DEPArray. It can however be anticipated that cell
loss might be more sample dependent in this setting as CTCs are
likely to exhibit more variation in morphology and immunofluor-
escent staining characteristics hampering their unambiguous
identification. It therefore stands to reason that, although it is not
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clear to define any specific lower limit for the number of CTCs at
this moment, the clinical applicability of this workflow will likely be
restricted to a limited subgroup of patients with metastatic
carcinomas in whom relatively high numbers of CTCs can be
found in the blood with the currently available enrichment
procedures.
Another point of notice is the long duration of DEPArray sorting
experiments, which in our experience amounts up to B1 working
day to obtain the current technical maximum of 18 isolations. This
becomes particularly relevant when transcriptional analysis is to be
performed on the isolated tumour cells, as it is unclear to what extent
RNA integrity will be affected and how gene expression profiles
might change under these conditions. Regardless of these potential
caveats, our results indicate that reliable transcriptional analysis of
tumour cells isolated with the DEPArray is at least feasible if
stringent criteria for RNA quality are applied. Based on a limited set
of nine well-chosen markers, gene expression profiles of MDA-MB-
231 cells were clearly separated from those of MCF7 cells and WBCs.
Observed gene expression profiles of cells from both breast cancer
cell lines were in agreement with those expected from literature
(Neve et al, 2006). Reassuringly, key molecular characteristics such as
the overexpression of ER cluster genes ESR1 and GATA3 in luminal
MCF7 cells and of CAV1 in basal-like MDA-MB-231 cells, as well as
the previously reported differences in EPCAM expression between
luminal and basal-like breast cancer cell lines (Sieuwerts et al, 2009a),
were highly preserved down to the single-cell level. This further
highlights the potential of this single cell approach for capturing
heterogeneity in the CTC population when appropriate markers are
selected.
More research and further optimisation are however needed
before these workflows can be applied to patient samples
containing unknown numbers and phenotypes of CTCs. First, an
important question to address for future research will be to explore
the molecular heterogeneity for specific biomarkers in clinical CTC
samples and how this heterogeneity compares with primary and/or
metastatic disease sites. Only such data will allow determining the
minimum number of CTCs that has to be characterised to obtain
clinically meaningful results from CTC-based biomarker analysis.
An important technical hurdle that has to be overcome is the low
performance of the applied EPCAM staining in CellSearch pre-
enriched cell samples. Workflows will also have to be optimised to
allow faster processing of samples and to minimise cell loss in
single-cell samples during the buffer reduction procedure when
preparing samples for downstream analysis. Furthermore, to
prepare samples for mutation analysis, a restriction-based,
ligation-mediated PCR amplification method was used. Although
we do not have specific data for this kit, all currently known WGA
methods are expected to deliver a method-specific genome
coverage and allelic representations (Spits and Sermon, 2009;
Vanneste et al, 2012), which might explain the failed detection or
misidentification of two out of four expected mutations in one of
the successfully amplified single-cell sample with the iPlex assay.
Evaluating different WGA methods might prove important to
circumvent this problem. Finally, in this study, the EPCAM-based
CellSearch system was used as the starting point for the CTC
purification and characterisation workflow. Using a model system
of human breast cancer cell lines, it has however been shown that
breast cancer cells of the normal-like subtype lack EPCAM
expression and that tumour cells of this breast cancer subtype
are consequently missed when using the standard CellSearch assay
(Sieuwerts et al, 2009a). It is furthermore suggested that in order to
be able to complete the different steps of tumour cell dissemina-
tion, epithelial cancer cells can undergo phenotypic changes that
are associated with the loss of epithelial markers, a process often
referred to as epithelial–mesenchymal transition (EMT) (Berx et al,
2007). Elevated gene expression of EMT-related transcription
factors and higher percentages of cells expressing stem cell markers
have recently been described in EPCAM- and CD45-depleted
peripheral blood cell fractions of patients with HER2þ MBC,
suggesting indeed the existence of an EPCAM-negative EMT-like
subpopulation of CTCs (Giordano et al, 2012). It will therefore be
of major interest for future research to combine different pre-
enrichment strategies with DEPArray cell sorting in order to be
able to specifically address questions regarding the relative
representation, molecular profile and biological properties of both
EPCAM-positive and EPCAM-negative CTC fractions isolated
from blood samples of patients with metastatic carcinomas.
In conclusion, we report on our first experiences with the
DEPArray system, a new dielectrophoretic cell sorter that allows the
isolation of single or small groups of cells from mixed-cell
suspensions. We describe analytical characteristics of the system
and provide proof of principle showing the feasibility to isolate and
molecularly characterise single tumour cells and groups of up to 10
tumour cells from CellSearch pre-enriched blood samples. Whereas
the merits of the system for complete elimination of the WBC
background from pre-enriched CTC samples and the opportunities
for translational research to study CTC heterogeneity are clearly
demonstrated, more research and further optimisation are needed
before these techniques can be applied in a clinical setting.
ACKNOWLEDGEMENTS
Dieter Peeters is a research assistant of the Fund for Scientific
Research Flanders (FWO Vlaanderen). We thank Roberto Salgado
and Aurore Dubois (Department of Pathology, Institut Jules
Bordet, Brussels, Belgium) for their assistance with the Therascreen
analyses. We gratefully acknowledge Elena Peruzzi and Manuela
Banzi (both from Silicon Biosystems, Bologna, Italy) for their help
with protocols and DEPArray system operation.
REFERENCES
Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M,
Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M (2012)
Prospective study evaluating the impact of tissue confirmation of
metastatic disease in patients with breast cancer. J Clin Oncol 30: 587–592.
Attard G, Swennenhuis JF, Olmos D, Reid AHM, Vickers E, A’Hern R, Levink
R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson
C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB,
Cooper CS, Molina A, Cox ME, LWMM Terstappen, de Bono JS (2009)
Characterization of ERG, AR and PTEN gene status in circulating tumor
cells from patients with castration-resistant prostate cancer. Cancer Res 69:
2912–2918.
Berx G, Raspe´ E, Christofori G, Thiery JP, Sleeman JP (2007) Pre-EMTing
metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp
Metastasis 24: 587–597.
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J,
Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW,
Meropol NJ (2008) Relationship of circulating tumor cells to tumor
response, progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol 26: 3213–3221.
Collisson EA, Cho RJ, Gray JW (2012) What are we learning from the cancer
genome? Nat Rev Clin Oncol 9: 621–630.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben
JM, Doyle GV, Allard WJ, LWMM Terstappen, Hayes DF (2004)
Circulating tumor cells, disease progression, and survival in metastatic
breast cancer. N Engl J Med 351: 781–791.
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H,
Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D (2008) Circulating
tumor cells predict survival benefit from treatment in metastatic
castration-resistant prostate cancer. Clin Cancer Res 14: 6302–6309.
Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I,
Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) The
molecular evolution of acquired resistance to targeted EGFR blockade in
colorectal cancers. Nature 486: 537–540.
BRITISH JOURNAL OF CANCER CTC isolation using dielectrophoretic cell sorting
1366 www.bjcancer.com |DOI:10.1038/bjc.2013.92
Fuchs AB, Romani A, Freida D, Medoro G, Abonnenc M, Altomare L,
Chartier I, Guergour D, Villiers C, Marche PN, Tartagni M, Guerrieri R,
Chatelain F, Manaresi N (2006) Electronic sorting and recovery of single
live cells from microlitre sized samples. Lab Chip 6: 121–126.
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De
Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S,
Mani SA, Esteva FJ, Cristofanilli M, Reuben JM (2012) Epithelial-
mesenchymal transition and stem cell markers in patients with HER2-
positive metastatic breast cancer. Mol Cancer Ther 11: 2526–2534.
Hannemann J, Meyer-Staeckling S, Kemming D, Alpers I, Joosse SA, Pospisil
H, Kurtz S, Go¨rndt J, Pu¨schel K, Riethdorf S, Pantel K, Brandt B (2011)
Quantitative high-resolution genomic analysis of single cancer cells. PLoS
One 6: e26362.
Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter
SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt
P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J,
Wolff AC, Park BH (2012) Detection of tumor PIK3CA status in metastatic
breast cancer using peripheral blood. Clin Cancer Res 18: 3462–3469.
Ignatiadis M, Rothe´ F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C,
Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J,
Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M,
Sotiriou C (2011) HER2-positive circulating tumor cells in breast cancer.
PLoS One 6: e15624.
Klein CA, Blankenstein TJF, Schmidt-Kittler O, Petronio M, Polzer B,
Stoecklein NH, Riethmu¨ller G (2002) Genetic heterogeneity of single
disseminated tumour cells in minimal residual cancer. Lancet 360: 683–689.
Kroneis T, Geigl JB, El-Heliebi A, Auer M, Ulz P, Schwarzbraun T, Dohr G,
Sedlmayr P (2011) Combined molecular genetic and cytogenetic analysis
from single cells after isothermal whole-genome amplification. Clin Chem
57: 1032–1041.
Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai G, Nakagawa K,
Fukuoka M (2004) Effect of re-treatment with gefitinib (‘Iressa,’ ZD1839)
after acquisition of resistance. Ann Oncol 15: 173–174.
La Thangue NB, Kerr DJ (2011) Predictive biomarkers: a paradigm shift
towards personalized cancer medicine. Nat Rev Clin Oncol 8: 587–596.
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV,
Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A,
Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA
(2008) Detection of mutations in EGFR in circulating lung-cancer cells. N
Engl J Med 359: 366–377.
Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a
looking glass for cancer? Nat Rev Cancer 12: 323–334.
Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev
Cancer 6: 449–458.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E,
Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen C-T,
Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M,
Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F,
Solit D, Bardelli A (2012) Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532–536.
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N,
Coppe J-P, Tong F, Speed T, Spellman PT, De Vries S, Lapuk A, Wang NJ,
Kuo W-L, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick
F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW
(2006) A collection of breast cancer cell lines for the study of functionally
distinct cancer subtypes. Cancer Cell 10: 515–527.
Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y,
Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT (2012) Loss of human
epidermal growth factor receptor 2 (HER2) expression in metastatic sites
of HER2-overexpressing primary breast tumors. J Clin Oncol 30: 593–599.
Pierga J-Y, Bonneton C, Magdele´nat H, Vincent-Salomon A, Nos C, Boudou
E, Pouillart P, Thiery J-P, De Cremoux P (2005) Real-time quantitative
PCR determination of urokinase-type plasminogen activator receptor
(uPAR) expression of isolated micrometastatic cells from bone marrow of
breast cancer patients. Int J Cancer 114: 291–298.
Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML,
Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM,
Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH,
Davis RW, Jeffrey SS (2012) Single cell profiling of circulating tumor cells:
transcriptional heterogeneity and diversity from breast cancer cell lines.
PLoS One 7: e33788.
Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer:
classification, prognostication, and prediction. Lancet 378: 1812–1823.
Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, Van Loo P, Van
Den Bossche M, Catthoor K, Sabbe B, Despierre E, Vergote I, Hilbush B,
Lambrechts D, Del-Favero J (2011) Optimized filtering reduces the error
rate in detecting genomic variants by short-read sequencing. Nat
Biotechnol 30: 61–68.
Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W,
Rizvi NA, Schwartz LH, Miller VA (2007) Prospective assessment of
discontinuation and reinitiation of erlotinib or gefitinib in patients with
acquired resistance to erlotinib or gefitinib followed by the addition of
everolimus. Clin Cancer Res 13: 5150–5155.
Riethdorf S, Fritsche H, Mu¨ller V, Rau T, Schindlbeck C, Rack B, Janni W,
Coith C, Beck K, Ja¨nicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K
(2007) Detection of circulating tumor cells in peripheral blood of patients
with metastatic breast cancer: a validation study of the CellSearch system.
Clin Cancer Res 13: 920–928.
Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T,
Ferrone S, Takata M, Uhara H, Okuyama R (2012) Mutation analysis of
BRAF and KIT in circulating melanoma cells at the single cell level. Br J
Cancer 106: 939–946.
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J,
Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A,
Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R,
Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N,
Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng S-WG,
Morin GB, Watson P, Gelmon K, Chia S, Chin S-F, Curtis C,
Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T,
Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF,
Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M,
Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution
spectrum of primary triple-negative breast cancers. Nature 486: 395–399.
Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens
JWM, Gratama J-W, Sleijfer S, Foekens JA (2009a) Anti-epithelial cell
adhesion molecule antibodies and the detection of circulating normal-like
breast tumor cells. J Natl Cancer Inst 101: 61–66.
Sieuwerts AM, Kraan J, Bolt-De Vries J, van der Spoel P, Mostert B, Martens
JWM, Gratama J-W, Sleijfer S, Foekens JA (2009b) Molecular
characterization of circulating tumor cells in large quantities of
contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res
Treat 118: 455–468.
Sieuwerts AM, Mostert B, Bolt-De Vries J, Peeters D, de Jongh FE, JML
Stouthard, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van
der Spoel P, Ramı´rez-Moreno R, van Deurzen CHM, Smid M, Yu JX, Jiang
J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, JWM Martens (2011)
mRNA and microRNA expression profiles in circulating tumor cells and
primary tumors of metastatic breast cancer patients. Clin Cancer Res 17:
3600–3618.
Spits C, Sermon K (2009) PGD for monogenic disorders: aspects of molecular
biology. Prenat Diagn 29: 50–56.
Vanneste E, Bittman L, Van der Aa N, Voet T, Vermeesch JR (2012) New
array approaches to explore single cells genomes. Front Genet 3: 44.
Wlodkowic D, Cooper JM (2010) Tumors on chips: oncology meets
microfluidics. Curr Opin Chem Biol 14: 556–567.
Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas
ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B,
Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy
S, Toner M, Maheswaran S, Haber DA (2012) RNA sequencing of
pancreatic circulating tumour cells implicates WNT signalling in
metastasis. Nature 487: 510–513.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
CTC isolation using dielectrophoretic cell sorting BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.92 1367
